KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EPS (Weighted Average and Diluted) (2016 - 2025)

Idexx Laboratories has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $3.09 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $3.09 for Q4 2025, up 17.94% from a year ago — trailing twelve months through Dec 2025 was $13.08 (up 22.59% YoY), and the annual figure for FY2025 was $13.08, up 22.59%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $3.09 at Idexx Laboratories, down from $3.4 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for IDXX hit a ceiling of $3.63 in Q2 2025 and a floor of $1.56 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $2.48 (2023), compared with a mean of $2.52.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 82.17% in 2021 and later tumbled 33.33% in 2022.
  • Idexx Laboratories' EPS (Weighted Average and Diluted) stood at $1.89 in 2021, then increased by 8.99% to $2.06 in 2022, then rose by 12.14% to $2.31 in 2023, then grew by 13.42% to $2.62 in 2024, then increased by 17.94% to $3.09 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $3.09 (Q4 2025), $3.4 (Q3 2025), and $3.63 (Q2 2025) per Business Quant data.